登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，3月4日，Liver injury in COVID-19: management and challenges》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-05

  • Liver injury in COVID-19: management and challenges

    Chao Zhang, Lei Shi, Fu-Sheng Wang

    Published:March 04, 2020DOI:https://doi.org/10.1016/S2468-1253(20)30057-1

    In December, 2019, an outbreak of a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], previously 2019-nCoV) started in Wuhan, China, and has since become a global threat to human health. The number of confirmed cases of 2019 coronavirus disease (COVID-19) has reached 87?137 worldwide as of March 1, 2020, according to WHO COVID-19 situation report 41; most of these patients are in Wuhan, China. Many cases of COVID-19 are acute and resolve quickly, but the disease can also be fatal, with a mortality rate of around 3%. Onset of severe disease can result in death due to massive alveolar damage and progressive respiratory failure.

  • 原文来源：https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30057-1/fulltext
133浏览量
原文链接
相关报告

  • 《LANCET，3月20日，COVID-19 and the liver: little cause for concern》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-21
    • COVID-19 and the liver: little cause for concern Mansoor N Bangash Jaimin Patel Dhruv Parekh Published:March 20, 2020DOI:https://doi.org/10.1016/S2468-1253(20)30084-4 The largest study on COVID-19 to date1 showed that the prevalence of elevated aminotransferases and bilirubin in people faring worst was at least double that of others. Although clinically significant liver dysfunction was not quantified, this and other studies have led some to suggest that this finding might present clinical challenges.2 Close inspection of the available data supports a higher prevalence of abnormal aminotransferase levels in severe COVID-19 disease, but these studies actually suggest that clinically significant liver injury is uncommon, even when data for the most severely ill patients are selected (table).
    110浏览量
    原文链接

  • 《LANCET，4月6日，Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-07
    • Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations Jason Phua, MRCP，Li Weng, MD，Lowell Ling, MRCP，Moritoki Egi, MD，Prof Chae-Man Lim, MD，Prof Jigeeshu Vasishtha Divatia, MD Published:April 06, 2020DOI:https://doi.org/10.1016/S2213-2600(20)30161-2 As coronavirus disease 2019 (COVID-19) spreads across the world, the intensive care unit (ICU) community must prepare for the challenges associated with this pandemic. Streamlining of workflows for rapid diagnosis and isolation, clinical management, and infection prevention will matter not only to patients with COVID-19, but also to health-care workers and other patients who are at risk from nosocomial transmission. Management of acute respiratory failure and haemodynamics is key. ICU practitioners, hospital administrators, governments, and policy makers must prepare for a substantial increase in critical care bed capacity, with a focus not just on infrastructure and supplies, but also on staff management. Critical care triage to allow the rationing of scarce ICU resources might be needed. Researchers must address unanswered questions, including the role of repurposed and experimental therapies. Collaboration at the local, regional, national, and international level offers the best chance of survival for the critically ill.
    57浏览量
    原文链接